Assembly Biosciences (ASMB) Lifted to “Hold” at BidaskClub
BidaskClub upgraded shares of Assembly Biosciences (NASDAQ:ASMB) from a sell rating to a hold rating in a research report released on Saturday morning.
ASMB has been the subject of a number of other reports. Zacks Investment Research downgraded Assembly Biosciences from a buy rating to a hold rating in a research report on Wednesday, February 20th. Leerink Swann started coverage on Assembly Biosciences in a research note on Monday, November 19th. They set an outperform rating and a $45.00 target price for the company. Three research analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. The stock currently has a consensus rating of Buy and an average target price of $47.00.
Shares of Assembly Biosciences stock opened at $20.23 on Friday. Assembly Biosciences has a one year low of $17.70 and a one year high of $63.15. The stock has a market cap of $516.69 million, a PE ratio of -5.08 and a beta of 1.77.
About Assembly Biosciences
Assembly Biosciences, Inc operates as a clinical stage biotechnology company. It develops oral therapeutic candidates for the treatment of hepatitis B virus (HBV) infection and novel class of oral synthetic live biotherapeutic candidates to treat disorders associated with the microbiome in the United States.
Recommended Story: Return On Assets
Receive News & Ratings for Assembly Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Assembly Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.